Table 2.
Outcome measures by treatment group.
| Clinical outcomes | Vitamin C (n = 36) | Placebo (n = 39) | Total (n = 75) | p value |
|---|---|---|---|---|
| Died in hospital | 0 (0%) | 2 (5%) | 2 (3%) | 0.494 |
| Died within 30 days of treatment initiation | 0 (0%) | 2 (5%) | 2 (3%) | 0.494 |
| Died within 90 days of treatment initiation | 0 (0%) | 4 (10%) | 4 (5%) | 0.116 |
| Admission to ICU | 2 (6%) | 4 (11%) | 6 (8%) | 0.675 |
| Admission to discharge (hours) Median (IQR) | 69 (48, 116) | 121 (69, 179) | 94 (56, 169) | 0.071 |
| Treatment to discharge (hours) Median (IQR) | 48 (24, 98) | 98 (46, 165) | 73 (26, 144) | 0.098 |
| Treatment to clinical stability (hours) Median (IQR) | 22 (-4, 90) | 49 (18, 137) | 41 (10, 98) | 0.083 |
| Plasma vitamin C after 24 h, N (%) (median IQR) a |
29 (81%) 226 (131, 461) |
32 (82%) 19 (10, 31) |
61(81%) 40 (17, 208) |
< 0.0001 |
| Follow-up | ||||
| Completed questionnaire N(%)b | 31 (86%) | 32 (86%) | 63 (86.3%) | 1 |
| Readmission within 30 daysb |
1 (3%) (day 24) |
4 (11%) (day 1 & 26) |
5 (8%) | 0.22 |
| Readmission for CAPb | 1 (2.7%) | 1 (2.7%) | 2 (2.7%) | 1 |
| Further antimicrobial therapy during follow-upc | 7 (19%) | 5 (14%) | 12 (19.0%) | 0.52 |
| No persisting symptomsc | 8 (22%) | 10 (27%) | 18 (29%) | 0.64 |
| Coughc | 12 (33%) | 10 (27%) | 22 (35%) | 0.57 |
| Chest painc | 3 (8%) | 5 (14%) | 8 (13%) | 0.51 |
| Shortness of breathc | 14 (39%) | 15 (41%) | 29 (46%) | 0.89 |
| Returned to normal activitiesc | 12 (33%) | 13 (35%) | 25 (40%) | 0.88 |
| Fatiguec | 20 (56%) | 14 (38%) | 34 (54%) | 0.14 |
Unless otherwise stated values presented are the number of participants (%).
aSamples were not available for vitamin C analysis for day 1 for 7 participants in the vitamin C group, and 7 in the placebo group.
bThe percentage was calculated after excluding those who had died.
cThe percentage was calculated for replies to that question only.